Klin Farmakol Farm. 2022;36(3):108-110 | DOI: 10.36290/far.2022.017

Use of taurolidine in the prevention and treatment of catheter infections

Jakub Víšek1, Lenka Ryšková2, Alena Machačová2, Martina Maříková3, Vladimír Blaha1
1 III. interní gerontometabolická klinika, FNHK a Lékařská fakulta v Hradci Králové, Univerzita Karlova v Praze
2 Ústav klinické mikrobiologie, FN a Lékařská fakulta v Hradci Králové, Univerzita Karlova v Praze
3 Oddělení klinické farmacie, Nemocniční lékárna Fakultní nemocnice Hradec Králové

The venous catheter is used for a variety of medical procedures. A dangerous complication of an implanted catheter with potentially very serious consequences is a catheter infection. Antimicrobial locks are used in the prevention and treatment of these infections. Taurolidine [bis- (1,1-dioxoperhydro-1,2,4-thiadiazinyl-4) -methane] is a derivative of the amino acid taurine. This substance replaces previously used antimicrobial locks with ethanol or antibiotics. It has broad antimicrobial effects. The mechanism of action is the binding of the hydroxymethyl group to the cell wall of the microorganism, which leads to its irreversible damage. The preventive use of taurolidine is associated with a fourfold reduction in the risk of catheter infection. Due to the minimal side effects, wide antimicrobial spectrum and the absence of resistance, it is gradually becoming the gold standard in the prevention and treatment of catheter infections.

Keywords: taurolidine, venous catheter, catheter infection, antimicrobial lock.

Accepted: November 3, 2022; Published: November 3, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Víšek J, Ryšková L, Machačová A, Maříková M, Blaha V. Use of taurolidine in the prevention and treatment of catheter infections. Klin Farmakol Farm. 2022;36(3):108-110. doi: 10.36290/far.2022.017.
Download citation

References

  1. Yoshida T, Silva AEBC, Simões LLP, Guimarães RA. Incidence of Central Venous Catheter-Related Bloodstream Infections: Evaluation of Bundle Prevention in Two Intensive Care Units in Central Brazil. ScientificWorldJournal. 2019:1025032. Go to original source... Go to PubMed...
  2. Maki DG, Kluger DM, Crnich CJ. The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc. 2006;81(9):1159-1171. Go to original source... Go to PubMed...
  3. Klevens RM, Edwards JR, Richards CL, Jr, Horan TC, Gaynes RP, Pollock DA, et al. Estimating health care-associated infections and deaths in US hospitals, 2002. Public Health Rep. 2007;122:160-166. Go to original source... Go to PubMed...
  4. Cai Y, Zhu M, Sun W, Cao X, Wu H. Study on the cost attributable to central venous catheter-related bloodstream infection and its influencing factors in a tertiary hospital in China. Health Qual Life Outcomes. 2018;16(1):198. Go to original source... Go to PubMed...
  5. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O'Grady NP, Raad II, Rijnders BJ, Sherertz RJ, Warren DK. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45. Erratum in: Clin Infect Dis. 2010;50(7):1079. Go to original source... Go to PubMed...
  6. Christensen LD, Holst M, Bech LF, Drustrup L, Nygaard L, Skallerup A, Rasmussen HH, Vinter-Jensen L. Comparison of complications associated with peripherally inserted central catheters and Hickman™ catheters in patients with intestinal failure receiving home parenteral nutrition. Six-year follow up study. Clin Nutr. 2016;35(4):912-917. Go to original source... Go to PubMed...
  7. Ruiz-Giardin J, Ochoa Chamorro I, Velázquez Ríos L et al. Blood stream infections associated with central and peripheral venous catheters. BMC Infect Dis. 2019;19:841. Go to original source... Go to PubMed...
  8. Olthof ED, Versleijen MW, Huisman-de Waal G, Feuth T, Kievit W, Wanten GJ. Taurolidine lock is superior to heparin lock in the prevention of catheter related bloodstream infections and occlusions. PLoS One. 2014;9(11):e111216. Go to original source... Go to PubMed...
  9. Gong L, Greenberg HE, Perhach JL, Waldman SA, Kraft WK. The pharmacokinetics of taurolidine metabolites in healthy volunteers. J Clin Pharmacol. 2007;47(6):697-703. Go to original source... Go to PubMed...
  10. Swift L, Zhang C, Kovalchuk O, Boklan J, Trippett T, Narendran A. Dual functionality of the antimicrobial agent taurolidine which demonstrates effective anti-tumor properties in pediatric neuroblastoma. Invest New Drugs. 2020;38(3):690-699. Go to original source... Go to PubMed...
  11. Braumann C, Gutt CN, Scheele J, et al. Taurolidine reduces the tumor stimulating cytokine interleukin-1beta in patients with resectable gastrointestinal cancer: a multicentre prospective randomized trial. World J Surg Onc. 2009;7:32. Go to original source... Go to PubMed...
  12. Liu Y, Zhang AQ, Cao L, Xia HT, Ma JJ. Taurolidine lock solutions for the prevention of catheter-related bloodstream infections: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2013;8(11):e79417. Go to original source... Go to PubMed...
  13. Morales-Borges RH. Taurine as Anticancer and Antiviral: Case Report and Prospective Update. Global Journal of Can­cer Case Reports. 2020;1(2):1-14. Go to original source...
  14. Blenkharn JI. Prevention of septic complications associated with TPN. JPEN J Parenter Enteral Nutr. 1986;10(4):436-437. Go to original source... Go to PubMed...
  15. Fahrner R, Möller A, Press AT, Kortgen A, Kiehntopf M, Rauchfuss F, Settmacher U, Mosig AS. Short-term treatment with taurolidine is associated with liver injury. BMC Pharmacol Toxicol. 2017;18(1):61. Go to original source... Go to PubMed...
  16. Pironi L, Boeykens K, Bozzetti F, Joly F, Klek S, Lal S, Lichota M, Mühlebach S, Van Gossum A, Wanten G, Wheatley C, Bischoff SC. ESPEN guideline on home parenteral nutrition. Clin Nutr. 2020;39(6):1645-1666. Go to original source... Go to PubMed...
  17. Wouters Y, Theilla M, Singer P, Tribler S, Jeppesen PB, Pironi L, Vinter-Jensen L, Rasmussen HH, Rahman F, Wanten GJA. Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition. Aliment Pharmacol Ther. 2018;48(4):410-422. Go to original source... Go to PubMed...
  18. Sun Y, Wan G, Liang L. Taurolidine lock solution for catheter-related bloodstream infections in pediatric patients: A meta-analysis. PLoS One. 2020;15(4):e0231110. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.